Research on the cell biology of tumors. Covers cancer-cell vulnerabilities, tumor spread, nanoreactor therapies, and AI-guided cancer research.
Researchers developed a method called 6mASCOPE that measures DNA tagging system accuracy and distinguishes bacterial from human DNA. The study found high levels of methylation in plant, fly, mouse, and human cells, but mostly attributed to contamination.
The Purdue Research Foundation Office of Technology Commercialization has awarded more than $143,000 to three projects led by researchers in the College of Agriculture, Engineering and Veterinary Medicine. Guri Johal is developing a corn variant that could impact worldwide corn production with Trask funds supporting his project on clon...
Scientists at University College London have developed a novel cancer therapy using magnetic seeds guided by an MRI scanner to heat and destroy tumours. The therapy, called MINIMA, has the potential to precisely treat hard-to-reach cancers with minimal side effects.
A study led by RCSI researchers found that almost half of tumours with metastatic breast cancer in the brain have changes in DNA repair pathways, making them vulnerable to PARP inhibitor drugs. This discovery opens up potential novel treatment strategies for patients with limited targeted therapy options.
Researchers found that macrophages feed on lactic acid produced by cancer cells, paralyzing killer immune cells and weakening tumour immunity. This discovery highlights the need to curb lactic acid production in tumours to improve immunotherapy outcomes.
Researchers found that hyaluronic acid is not only present in pancreatic tumors but also serves as a nutrient source for cancer cells. This discovery indicates potential new treatments for pancreatic cancer by targeting the sugar scavenging pathway.
A research team has developed a new cancer treatment that targets lymph nodes using a prodrug that selectively reacts with glutathione to release nitric oxide. In a metastasis mouse model, the mice treated with the drug showed significantly reduced weight of metastatic cancer cells and improved survival rates.
Researchers used optical imaging to study the metabolic interactions between pancreatic cancer cells and surrounding non-cancer cells. They found that cancer cells can hijack the metabolic activity of these non-cancer cells to fuel tumor growth. This discovery could lead to new therapies targeting the tumor microenvironment.
Researchers have identified nine new factors involved in DNA repair, a critical process for human cell health. The findings can help develop new cancer drugs and improve existing therapies.
Sophie Paczesny's research aims to validate biomarker panels that help doctors predict chronic GVHD risk and adjust immune suppression treatments accordingly. The study uses machine learning algorithms to analyze stored plasma and blood cell samples from over 1,300 BMT recipients.
Researchers developed a multifunctional microfiber probe for real-time monitoring of cellular molecules and changes in cell morphology. The nanowire probe enabled sensitive detection of refractive index distribution in single living cells during apoptosis.
Researchers discovered that IgA and IgG antibodies regulate immune responses against endometrial cancer, improving outcomes when tumor cells express the antibody receptor pIgR. The study suggests new therapies targeting B cells or combinations with T-cell immunotherapies for enhanced efficacy.
Researchers at UTA have discovered commonalities among caspases 3, 6, and 7 that could allow for the isolated activation of proteins in tumor cells without disrupting healthy cells. By understanding how effector caspases work in healthy conditions, they hope to develop methods to destroy abnormal cells while preserving healthy ones.
Researchers at Cold Spring Harbor Laboratory discovered a previously unknown protein called SCP4 that plays a crucial role in the survival of acute myeloid leukemia cells. The study found that SCP4 can pair with specific kinases to regulate cell activity, and targeting this pathway may lead to effective treatment options.
The new technology can reliably distinguish between cancerous and healthy liver tissue, aiding diagnosis and potentially reducing errors in biopsies. The researchers plan to continue measuring fluorescence lifetime parameters in patients with different types of tumors to generate real-time diagnostic classifiers.
Researchers developed a color-coded test that quickly signals whether medical nanoparticles deliver their cargo into target cells. The tool, tested in mouse cells and living mice, assesses nanoparticle formulations on their ability to escape cellular defenses and reach the cell's interior.
Researchers discovered that aberrant splicing of CD22 mRNA leads to decreased protein expression in pediatric B-lymphoblastic leukemia cells. This results in resistance to CD22-directed immunotherapies, making it challenging for oncologists to identify patients who may not respond to these treatments.
A study from Weill Cornell Medicine and Cornell University reveals that targeting protein ATF4 and its related metabolic protein SIRT3 can trick lymphoma cells into starving themselves, slowing their growth.
Researchers discover a chromatin degrader that blocks cancer-causing genes, offering potential treatment for over 90% of prostate cancers. The study found that blocking the SWI/SNF complex slowed cancer cell growth and induced cell death, especially in tumors driven by FOXA1 or androgen receptor.
Scientists at La Jolla Institute for Immunology have discovered a link between TET enzyme deficiency and the formation of unusual DNA structures, such as G-quadruplexes and R-loops, which contribute to genomic instability. The study suggests that regulating these structures may be key to controlling cancer development.
A marine-dwelling creature, Trichoplax adhaerens, has been found to resist cancer and repair DNA after radiation damage. Researchers are exploring its unique properties to develop new therapies for cancer.
Researchers have identified NDUFS1 and ATP5O as novel markers of aggressive prostate cancer, associated with poorer survival rates. The study's findings provide new insights into the disease's molecular mechanisms and potential targets for therapy.
Researchers analyzed the largest cross-species database to assess species-specific cancer mortality rates and found conclusive proof that cancer risk is largely independent of body mass and life expectancy. The study highlights potent mechanisms of cancer resistance in larger species, contradicting intuitive expectations.
Researchers discover tBID can induce programmed cell death through mitochondrial damage, revealing a new function for a previously thought signal transducer protein. This finding has implications for treating malignant cells and combating infections like Shigella.
Scientists have developed a pioneering new technique to barcode individual cells more accurately and efficiently. The method combines artificial intelligence with microfluidics, allowing for real-time analysis of single cells and enabling the efficient sorting and counting of cells.
A recent study has identified a new mechanism by which oral cancer cells acquire radioresistance through the transfer of microRNA, specifically miR-503-3p. This discovery brings hope for the development of new treatments for radiation-resistant oral cancer.
Researchers have identified a novel immune-like mechanism by which healthy epithelial cells recognize and eliminate precancerous cells through a MHC class I-LILRB3 interaction. This process generates mechanical force to extrude the precancerous cells from the body, offering new hope for cancer prevention and treatment.
Researchers mapped how HTLV-1 transforms T-cells into cancerous cells, revealing the virus over-activates them and makes them more vulnerable to DNA damage. This study provides new directions for potential treatments to prevent cancer development.
Researchers identified specific metabolic vulnerabilities in leukemia cell lines, including sensitivity to PI3K and fatty acid synthase inhibitors. The study highlights the potential for targeted cancer therapy by exploiting these dependencies.
Researchers have discovered that NOR-1 protein can provide broad protection against heart damage following cancer treatment. Administering the protein directly may reduce heart risk, at least in laboratory tests.
Researchers analyzed 140 neuroblastoma samples to understand the genetic changes associated with the disease. They found that mutations can disappear and reappear, occurring in distinct sections or individual cells, making targeted therapy less effective.
Researchers identified three prototypical RNA-expression states in pancreatic cancer cells and found that altering the tumor microenvironment can drive tumor cells to become more susceptible to certain drugs. This discovery opens up new possibilities for personalized medicine and targeting specific drug responses.
Researchers have developed a CRISPR/Cas9 gene editing system to enhance the effectiveness of sonodynamic therapy, allowing tumors to be effectively shrunk in a mouse model of liver cancer. The technology reduces antioxidant defense systems, increasing cancer cell death from the treatment.
A recent study by NTU Singapore and Singapore General Hospital found that mutations in the DDX3X gene are responsible for chemotherapy resistance in some blood cancer patients. The study also discovered that STAT inhibitors can effectively kill lymphoma cells with DDX3X mutations, providing hope for new treatment options.
Researchers discovered a newly defined domain in a protein that regulates gene expression under high-energy conditions. Cells adapt to changing nutrient environments by switching between specialized gene expression programs, which are triggered by different molecular tags on histones.
Researchers identified a mechanism for how genetically defective cells mutate to survive stressful situations, such as drug treatment. Understanding this resistance mechanism could lead to the development of new strategies to delay or prevent cancer drug resistance.
Researchers at Tel-Aviv University have shed light on the Sigma-1 receptor's topology and function in neurodegenerative diseases. The study reveals that the receptor is retained in the endoplasmic reticulum and its amino end faces the cytoplasm, providing a crucial mechanism for therapeutic approaches to alleviate suffering from ALS.
A research team developed an AI framework that analyzes protein interactions to predict effective and low-toxicity cancer drug combinations. The framework, GraphSynergy, outperforms conventional models in identifying synergistic combinations.
The FDA has approved Cytalux, which enables surgeons to identify and remove cancerous lesions with greater precision. In a Phase 3 study, nearly 27% of women with confirmed ovarian cancer found at least one undetected lesion during surgery.
The study uses a new barcode system to track complex signaling activities in cancer cells and identify key protein interactions. The technique enables real-time analysis and synchronization of protein activity over time.
Researchers at Saarland University have discovered that the lipid and cholesterol metabolism of immune cells collaborating with tumour cells is severely compromised compared to tumour tissue. This finding suggests a possible explanation for why cholesterol-lowering drugs are ineffective against non-small-cell lung carcinoma.
A recent review article describes a class of viruses known as oncolytic viruses, which have the remarkable ability to target and destroy cancer cells. Researchers are exploring these viruses for cancer therapy, with some showing promising results in stimulating an immune response against cancer.
A study found that the MYCN protein creates conflicts between DNA replication and transcription in cancer cells, leading to increased division rates and potential damage. The researchers hope to develop therapies by disrupting the cooperation between MYCN and a molecule called BRCA1.
Researchers discovered that under stress conditions, proteasome molecules assemble into structures that induce cell death, a process linked to apoptosis and potentially preventing cancer. The study highlights the importance of understanding the normal functioning of cells and their connections to cancer development.
A systematic review of bitter taste receptors in cancer found that overexpression of these receptors stimulates anti-cancer mechanisms, reducing cell division and migration while increasing programmed cell death. Conversely, downregulation of bitter taste receptor genes is common in cancer cells.
Researchers from the University of Copenhagen have discovered a natural substance, a flavonoid, that can inhibit cancer cells' ability to defend themselves against chemotherapy by targeting efflux pumps. This could lead to more effective treatment and potentially even combat antibiotic resistance.
Cryo-EM study reveals details of DNA repair mechanism translesion synthesis (TLS), allowing cells to survive with mutations. Key protein complex Pol K - PCNA interaction modulated by ubiquitination facilitates recruitment of TLS polymerase to damage sites.
Researchers at Karolinska Institutet found that CRISPR gene-editing causes DNA damage, activating the p53 protein, which can lead to an accumulation of mutated cancer cells. The study identified a network of linked genes with similar mutations and suggests transient inhibition of p53 as a potential strategy to prevent their enrichment.
A functional precision medicine study demonstrates that treatment selection based on results from drug sensitivity testing can be clinically useful in patients with aggressive hematological cancer. The approach combines deep molecular profiling with comprehensive drug sensitivity testing to advance the therapy decision-making system.
Researchers have developed fish-shaped microrobots that can guide themselves to cancer cells using magnets, where a pH change opens their mouths to release chemotherapy. The microrobots demonstrate promising capabilities for targeted cancer treatment, but need further improvements in size and tracking methods.
Researchers have developed a new approach to studying prostate cancer, allowing them to track the behavior of individual cancer cells from birth to organ spread. The technique uses whole-organ imaging and artificial intelligence to create a 3D reconstruction of the organ at single-cell resolution.
A researcher at MUSC's Hollings Cancer Center is developing 'living drugs' by precision-engineering CAR Tregs to treat autoimmune diseases. The CAR Tregs can delay or reduce damaging inflammation, offering a potential solution for conditions like Type 1 diabetes.
A recent study by Sanford Burnham Prebys and the National Cancer Institute has shown that CRISPR-Cas9 gene editing can favor cells with mutated forms of genes linked to cancer. This highlights the importance of monitoring patients undergoing CRISPR-based gene therapy for cancer-related mutations.
Researchers at University of Göttingen investigate tight junctions' importance in cell movement and their consequences when missing. The findings suggest a 'tug of war' scenario between cells with unequal contraction and stretching, affecting tissue mobility and biological functions.
Researchers developed a blood test that can detect prostate cancer patients who are resistant to chemotherapy drug docetaxel, enabling early detection and personalized treatment. The test analyzes circulating tumor cells in the bloodstream, revealing patterns that predict disease progression and survival.
A research team at the University of Montreal Hospital Research Centre has found that cellular aging is caused by irreversible damage to the genome, not just telomere erosion. This discovery challenges the long-held scientific model and opens up new research opportunities for preventing cellular aging and genomic instability.
Researchers at Johns Hopkins Kimmel Cancer Center found a new treatment option for inoperable pleural mesothelioma using immunotherapy agent durvalumab combined with platinum-based chemotherapy. Patients with epithelioid tumors experienced higher survival rates, including some who remained tumor-free after completing the trial.
Researchers discovered a new biomarker, inactive AMPK (lo-P-AMPK), that may predict immune evasion in lung cancer. The finding could enable better personalized care for lung cancer patients by identifying those most likely to benefit from immunotherapies.
A new machine learning model developed by Timothy Chan accurately predicts whether immune checkpoint blockade will be effective in patients with various cancers. The tool assesses multiple patient-specific factors, including tumor mutational burden and chemotherapy history, to predict response and survival outcomes.
Researchers at Children's Hospital of Philadelphia have developed a novel therapy that targets proteins essential for tumor growth and survival. Using a multi-omics approach, they identified peptides unique to neuroblastoma tumors, which are then targeted by peptide-centric chimeric antigen receptors (PC-CARs).